Karinna Chouman1, Birgit Korioth-Schmitz1, Markus Sack2, Jörn Engelbert Schmitz1, Anh Tuan Pham1, Rainer Fischer2,4, Stefan Barth5, Torsten Klockenbring1, Rolf Fendel1,6
European Cytokine Network, Vol.29, No.2, pp. 59-72, 2018, DOI:10.1684/ecn.2018.0409
Abstract Interleukin-6 (IL-6) expression and secretion, induced by inflammatory processes, stimulate the acute
phase response cascade. The overexpression of IL-6 contributes to a variety of inflammatory diseases, e.g. rheumatoid
arthritis, Castleman’s disease, multiple myeloma, and prostate cancer. Screening for high amounts of IL-6 in
the patients’ blood serum can be crucial for an adequate treatment. In this study, five novel murine monoclonal
antibodies (mAbs) reactive to human IL-6 were generated. The mAbs were characterized for potential diagnostic
purposes and recombinant antibodies were derived thereof. Initial epitope mapping using a combination of blocking
experiments and Hyper-IL-6, a fusion… More >